This Is MS Multiple Sclerosis Knowledge & Support Community
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge. https://www.thisisms.com/forum/
1st Venous Endovascular Forum in Katowice, Poland.
the website lists the speakers, which seems to contain some great CCSVI minds aswell as some neuros, the feedback should be very interesting.
Posted: Fri Mar 04, 2011 9:04 pm
by CD
Yes, look what's coming ahead in Europe:
VEF Conference, Poland, March 3 and 4
March 3:
14:00-17:30 CCSVI Diagnostic workshops:
MRI equipment preparation in order to perform MRI diagnostic tests.
Doppler Ultrasound equipment preparation and Doppler USG examination training
19:00-23:00 Welcome Reception.
March 4:
09:00-09:10 What do we know and do not know about CCSVI?
(Assoc. Prof. Marian Simka, MD, PhD, Poland)
09:10-09:30 Fighting for Treatment of CCSVI in Canada: Untangling Science and Politics.
(Kirsty Duncan, MD, PhD, Canada)
09:30-09:50 Imaging as a Treatment Planning Tool for CCSVI.
(Prof. E. Mark Haacke, MD, PhD, USA)
09:50-10:30 Neurological panel
Controversy on the prevalence of CCSVI in MS.
(Prof. Danuta Ryglewicz, MD, PhD, Poland)
Clinical picture and up-today diagnostic of MS.
(Prof. Jerzy Kotowicz, MD, PhD, Poland)
What we should assess doing follow-up in MS patients.
(Jacek Zaborski, MD, PhD, Poland)
Current concepts in MS pathogenesis.
(Assoc. Prof. Konrad Rejdak, MD, PhD, Poland)
Ultrasound examination of cerebral venous hemodynamics.
(Joanna Wojczal, MD, PhD, Poland)
10:50-11:00 Angiographic findings of CCSVI: Characterization of venous lesions in CCSVI and review of angiographic findings of CCSVI.
(Ma'moon Hasan Al-Omari, MD, PhD, Jordan)
11:00-11:10 Early and mid term results of Endovascular treatment in patients with CCSVI and MS. Experience in Tokuda Hospital.
(Assoc. Prof. Ivo Petrov, MD, PhD, Bulgaria)
11:10-11:20 How we treat CCSVI in India.
(Vikas Gupta, MD, PhD, India)
11:20-11:30 CCSVI in Argentina. Argenmedic - our working progress.
(Prof. Cristian Schulte, MD, PhD, Argentina)
11:30-11:40 How we treat CCSVI in UK.
(Thomas Cormac Gilhooly, MD, PhD, United Kingdom)
11:40-11:50 Improvement of chronic fatigue after the treatment for CCSVI.
(Prof. Miro Denišlič, MD, PhD, Slovenia)
11:50-12:00 Results of the world survey on diagnostics and interventions for CCSVI.
(Assoc. Prof. Marian Simka, MD, PhD, Poland)
12:00-12:40 Discussion panel.
12:40-13:30 Live case I-transmission of the CCSVI treatment from Euromedic Clinic.
14:30-14:45 Presentation of problems, complications and difficulties encountered during CCSVI endovascular procedure..
(Tomasz Ludyga, MD, PhD, Poland)
14:45-15:00 Thrombosis and intimal hyperplasia following endovascular treatments for CCSVI: which prophylaxis could be the best one?
(Assoc. Prof. Tomasz Urbanek, MD, PhD, Poland)
15:00-15:50 Live case II- transmission of the CCSVI treatment from Euromedic Clinic..
15:50-16:00 Ophthalmological findings..
(Aneta Adamczyk-Ludyga, MD, PhD, Poland)
16:00-16:10 Does venous pathology play a role in the pathogenesis of multiple sclerosis?
(Assoc. Prof. Marian Simka, MD, PhD, Poland)
16:30-16:40 Blood gas analysis in patients with Chronic Cerebro-spinal Venous Insufficiency
(Prof. Lachezar Grozdinski, MD, PhD, Bulgaria)
16:40-16:50 Venous hypertension in the central nervous system - a symptom or disease entity?
(Prof. Krzysztof Ziaja, MD, PhD, Poland)
16:50-17:00 Changes in physical, mental and neurological status in MS patients six months after endovascular procedure.
(Jacek Kostecki, MD, PhD, Poland)
17:00-17:10 How to improve the results and avoid problems: what have we learnt during last year.
(Tomasz Ludyga, MD, PhD, Poland)
17:10-18:00 "Round table" discussion – summary of:
Formal and medical guidelines for further action
New areas of application of balloon angioplasty and stenting; Parkinson disease?, Sclerosis lateralis amyotrophica? Alzheimer disease?
Multicentre research
New materials (stents, balloons)
Implement the CCSVI procedure as a universally available treatment
18:00-18:15 The Conference Closing Ceremony.
20:30-02:00 Silesian night – dinner and concert in Monopol Hotel, Katowice
Erika, great find! This is a whole pdf of his presentation:
WHAT DO WE KNOW AND DO
NOT KNOW ABOUT CCSVI?
Marian Simka
What we do not know:
• Is CCSVI the causal factor for MS, a co-factor or an
epiphenomenon
...
I understand what it would mean if CCVSI is causal, I think co-factor means there are more than one factors causing MS but CCSVI would be included in them, and epiphenomon must mean CCSVI would be caused by the MS?? I am guessing on that last one.
Are we undertreating or overtreating the
patients ?
I've made this point here myself, I agree, this is not yet known and it needs to be worked out. This is one of the reasons I am as big a fan as I am of IVUS, it takes some of the guesswork out of what the IRs are doing because they can see more clearly, if they know what they are looking for on IVUS.
He has a bunch of points, all very good, this is an easy read and worth the reading.
• Are treatments for CCSVI efficient in a long-
term perspective ?
• Which subgroups of the patients can benefit
and which cannot ?
I think every subgroup will benefit from increases in CNS oxygenation. It's all in how benefit is defined.
Posted: Fri Mar 18, 2011 11:10 am
by Cece
Here too is Dr. Ludyga's presentation on opthalmological findings and optical coherence tomography!
220 MS patients were performed catheter
venography to diagnose and evaluate CCSVI and OCT
( GCC AVG, GCC FLV, GCC GLV and RNFL AVG )
• Ocular pathologies were found more often in the
cases of:
- CCSVI limited to only one internal jugular vein,
especially in the cases of severe outflow blockage of
this vein
- asymetric blockages of internal jugular veins
• Venous anomalies of the azygous vein were not
associated with higher risk of ocular pathology.
• MS patients who were not diagnosed with CCSVI
showed exceptionally high prevalence of OCT
abnormalities.
High percentages of retinal pathologies in
non-CCSVI patients indicate that the
mechanism of retinal neurodegeneration in
MS is far more complex and cannot be
expained as an obvious vascular pathology
some of my questions --
* Are there MS patients who do not have CCSVI? (I do not think this has been answered yet.) (Misdiagnosis of MS would be excluded.)
* Why would ocular pathologies be more common if only one jugular is occluded compared to if both jugulars are occluded? How odd.
VEF Conference TV report
Posted: Fri Mar 18, 2011 12:20 pm
by ErikaSlovakia
VEF Conference TV report
Erika
VEF Conference
Posted: Thu Apr 21, 2011 4:58 am
by EuroMedic
• Please find dr Aneta Adamczyk-Ludyga VEF presentation clicking the link below.